Deal Size Increased to 11.25M Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Should l Buy ALMR?
The deal size was increased to 11.25M shares of common stock from 9.375M shares of common stock and priced at the high-end of the $15.00-$17.00 range. JPMorgan, BofA, TD Cowen, Leerink and Stifel acted as joint book running managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALMR
Wall Street analysts forecast ALMR stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 17.000
Low
Averages
High
Current: 17.000
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alamar Biosciences Plans $150 Million IPO to Advance Protein Biomarker Detection
- IPO Fundraising Goal: Alamar Biosciences announced plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17, aimed at supporting the development and commercialization of its protein biomarker detection platform.
- Technological Edge: The company's proteomics technology enables the detection and analysis of protein biomarkers at very low concentrations in biological samples, combining proprietary instruments, consumables, and software to provide an end-to-end system for measuring multiple low-abundance proteins, enhancing disease detection accuracy.
- Market Potential: Alamar Biosciences' technology spans a wide range of applications from early-stage discovery to translational research, emphasizing the need for more precise and consistent protein detection in clinical applications to meet the growing healthcare demands.
- Financial Performance: Founded in 2018, the company reported $74 million in revenue for the 12 months ending December 31, 2025, indicating its rapid growth potential in the biotechnology sector.
See More
Alamar Biosciences Shares Surge 40% After IPO Pricing
- Successful IPO Pricing: Alamar Biosciences priced its upsized IPO at $17 per share for approximately 11.3 million shares, aiming to raise around $191 million in gross proceeds, exceeding its initial target of $159 million, indicating strong market confidence in its business model.
- Impressive Stock Performance: The company's shares opened at $22.60, reflecting a 33% increase from the offering price, and closed at $23.65 around 1:20 PM ET, marking a ~40% jump and a market capitalization exceeding $1.6 billion, showcasing investor optimism about future growth.
- Significant Technological Edge: Alamar's NULISA technology, capable of detecting and quantifying over 100 protein biomarkers in a single biofluid sample, underpins its ARGO HT System, which is expected to enhance the company's competitiveness in the rapidly growing proteomics market.
- Strong Revenue Growth: In 2025, Alamar generated $74.2 million in revenue, achieving over 195% year-over-year growth, primarily driven by the successful rollout of the ARGO HT System, indicating effective market expansion and technology application.
See More
Alamar Biosciences Prices Upsized IPO at $17.00
- Successful IPO Pricing: Alamar Biosciences priced its upsized initial public offering at $17.00 per share for approximately 11.3 million shares, aiming to raise about $191 million in gross proceeds, reflecting strong market demand for its protein detection and analysis technologies.
- Trading Debut: The company is set to debut on the Nasdaq Global Select under the ticker symbol “ALMR” on Friday, marking a significant milestone in its commercial stage and laying the groundwork for future growth.
- Underwriter Option: Underwriters will have a 30-day option to purchase an additional ~1.7 million shares at the IPO price, providing the company with added financial flexibility and enhancing its capital structure.
- Adjusted Fundraising Goals: Earlier this week, Alamar aimed to offer ~9.4 million shares at a targeted price range of $15–$17, potentially raising up to $159 million at the top of the range, demonstrating the company's keen market insight and adaptability.
See More
Alamar Biosciences Raises $191 Million in IPO at High End of Range
- Significant Fundraising: Alamar Biosciences successfully raised $191 million by offering 11.3 million shares at $17 each, reaching the high end of its $15 to $17 range, indicating strong market demand for its protein biomarker detection platform.
- Oversubscription Success: The number of shares sold exceeded the original plan of 9.4 million by 20%, reflecting investor confidence in Alamar's proteomics technology, thereby strengthening the company's capital base to support future R&D.
- Technological Platform Advantage: Alamar's platform integrates proprietary instruments, consumables, and software to detect and analyze low-abundance protein biomarkers in biological samples, applicable across various fields from early-stage discovery to translational research, enhancing precision and consistency in disease detection.
- Clear Market Positioning: Based in Fremont, CA, the company plans to trade on Nasdaq under the symbol ALMR, and with this fundraising, Alamar aims to further solidify its market position in biomedical research and clinical applications.
See More
Alamar Biosciences Plans $150 Million IPO to Advance Protein Biomarker Detection
- IPO Fundraising Goal: Alamar Biosciences announced plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17, aimed at supporting the development and commercialization of its protein biomarker detection platform.
- Technological Edge: The company's proteomics technology enables the detection and analysis of protein biomarkers at very low concentrations in biological samples, combining proprietary instruments, consumables, and software to provide an end-to-end system for measuring multiple low-abundance proteins, enhancing disease detection accuracy.
- Market Potential: Alamar Biosciences' technology spans a wide range of applications from early-stage discovery to translational research, emphasizing the need for more precise and consistent protein detection in clinical applications to meet the growing healthcare demands.
- Financial Performance: Founded in 2018, the company reported $74 million in revenue for the 12 months ending December 31, 2025, indicating its rapid growth potential in the biotechnology sector.
See More
Alamar Biosciences Shares Surge 40% After IPO Pricing
- Successful IPO Pricing: Alamar Biosciences priced its upsized IPO at $17 per share for approximately 11.3 million shares, aiming to raise around $191 million in gross proceeds, exceeding its initial target of $159 million, indicating strong market confidence in its business model.
- Impressive Stock Performance: The company's shares opened at $22.60, reflecting a 33% increase from the offering price, and closed at $23.65 around 1:20 PM ET, marking a ~40% jump and a market capitalization exceeding $1.6 billion, showcasing investor optimism about future growth.
- Significant Technological Edge: Alamar's NULISA technology, capable of detecting and quantifying over 100 protein biomarkers in a single biofluid sample, underpins its ARGO HT System, which is expected to enhance the company's competitiveness in the rapidly growing proteomics market.
- Strong Revenue Growth: In 2025, Alamar generated $74.2 million in revenue, achieving over 195% year-over-year growth, primarily driven by the successful rollout of the ARGO HT System, indicating effective market expansion and technology application.
See More
Alamar Biosciences Prices Upsized IPO at $17.00
- Successful IPO Pricing: Alamar Biosciences priced its upsized initial public offering at $17.00 per share for approximately 11.3 million shares, aiming to raise about $191 million in gross proceeds, reflecting strong market demand for its protein detection and analysis technologies.
- Trading Debut: The company is set to debut on the Nasdaq Global Select under the ticker symbol “ALMR” on Friday, marking a significant milestone in its commercial stage and laying the groundwork for future growth.
- Underwriter Option: Underwriters will have a 30-day option to purchase an additional ~1.7 million shares at the IPO price, providing the company with added financial flexibility and enhancing its capital structure.
- Adjusted Fundraising Goals: Earlier this week, Alamar aimed to offer ~9.4 million shares at a targeted price range of $15–$17, potentially raising up to $159 million at the top of the range, demonstrating the company's keen market insight and adaptability.
See More
Alamar Biosciences Raises $191 Million in IPO at High End of Range
- Significant Fundraising: Alamar Biosciences successfully raised $191 million by offering 11.3 million shares at $17 each, reaching the high end of its $15 to $17 range, indicating strong market demand for its protein biomarker detection platform.
- Oversubscription Success: The number of shares sold exceeded the original plan of 9.4 million by 20%, reflecting investor confidence in Alamar's proteomics technology, thereby strengthening the company's capital base to support future R&D.
- Technological Platform Advantage: Alamar's platform integrates proprietary instruments, consumables, and software to detect and analyze low-abundance protein biomarkers in biological samples, applicable across various fields from early-stage discovery to translational research, enhancing precision and consistency in disease detection.
- Clear Market Positioning: Based in Fremont, CA, the company plans to trade on Nasdaq under the symbol ALMR, and with this fundraising, Alamar aims to further solidify its market position in biomedical research and clinical applications.
See More
